Who are the Five Makers Building Momentum of Food Ingredient Market.

Food Ingredient Market: Five Makers Building Momentum

On 22 October, Kerry Group told the market its volumes grew 4.1% in the third quarter, ahead of its end markets, and signalled a further share buyback of up to €300 million. Three months earlier, Givaudan had opened a new flavour plant in Indonesia. The food ingredient market is forecast to grow at 4.941% a year, dependable rather than dramatic; yet the companies inside it are committing capital at a pace the headline rate does not explain. Our analysis of five makers named in the 2026 report shows what they are actually buying.

Why are ingredient makers investing while demand looks steady?

The global frame is calm. Our Food Ingredient Market Analysis puts the market at $35,240.7 million in 2025 and $51,833.3 million by 2033, growing at 4.941% a year.

Underneath that average, the composition of demand is changing faster than the volume of it. The report’s ten type segments from Nutrients and Flavors through Sweeteners, Thickeners and Stabilizers are not growing in step, and the Nutraceuticals application behaves differently from Food and Beverages.

In our primary research with formulation and procurement teams, the brief has shifted from supply to capability. Buyers ask who can rebuild a product at production scale without losing taste, texture or shelf life, and whether that help is available in the region where the line runs.

That is a capability question, and capability has to be built or bought. Which is why the money is moving into regional plants, fermentation platforms, premix facilities and portfolio acquisitions rather than into volume.

Which ingredient makers are building momentum in the food ingredient market?

Five profiles follow, in no particular order, they are presented alphabetically, and each is described by its own strengths rather than against the others.

Givaudan

Givaudan creates flavours and taste systems, serving the Flavors line of the report’s type segmentation across the Food and Beverages application.

Its distinctive capability is proximity: creation centres and manufacturing sited close to the customers doing the formulating, in both powder and liquid formats.

Two dated commitments show the pattern. On 3 July 2026 the company opened a CHF 50 million production facility in Cikarang, Indonesia, spanning 24,000 square metres on a 50,000 square metre site and creating around 60 jobs initially. It produces savoury, sweet and snack flavour powders, and the company tied it explicitly to a 2030 strategy of increasing presence in strategic high-growth markets.

Then on 15 September 2026 Givaudan acquired land at West Harrison, Indiana for a liquids production facility, an initial investment of CHF 187 million (US$215 million) across 24,000 square metres, creating approximately 250 jobs. Construction is anticipated to begin in 2026 with partial operations from 2028. Cedric Koller, who heads Taste & Wellbeing operations, framed it as significantly enhancing liquid production capacity and accelerating speed-to-market.

Givaudan already manufactures liquids, powder blends and spray-dried flavours at Cimanggis in West Java and runs a creation and innovation centre in Jakarta; its Taste & Wellbeing business held 17 locations across the United States and Canada before the Indiana project.

The signal for the wider market is that flavour capacity is being built beside demand rather than shipped into it.

Glanbia

Glanbia supplies nutritional ingredients custom premix solutions, whey protein isolate and clean-label flavour systems mapping to the report’s Nutrients segment and its Nutraceuticals application.

Its distinctive capability is the bespoke premix: functionally optimised nutrient blends built to a customer’s specification rather than sold from a catalogue.

The half-year results published on 6 August 2026, covering the six months to 4 July, carry the figures. Adjusted earnings per share reached 81.24 US cents against 63.03 cents a year earlier, an increase of 30.0%. Health & Nutrition delivered like-for-like revenue growth of 12.0% with volume up 14.3% and an EBITDA margin of 18.4%, while Performance Nutrition grew like-for-like revenue 16.9%. The group upgraded full-year adjusted EPS guidance to 17% to 20% growth and raised its transformation savings target from $60 million to $70 million a year by FY2027.

Capacity work is running in the United States, China and Europe, supported by two acquisitions. Sweetmix, a nutritional premix and ingredient solutions business at Sorocaba in Brazil, was bought for initial consideration of $41.4 million plus deferred consideration, closing in January 2026. Scicore, a manufacturing facility in India, was announced in November 2025 and completed for total consideration of approximately $16.4 million.

Glanbia serves active nutrition, functional beverage and vitamin brands that need a documented blend. Its moves say premix is going in-market customers increasingly want the blend made in the region that consumes it.

Kerry Group

Kerry supplies taste and nutrition systems to food, beverage and pharmaceutical manufacturers, spanning savoury taste, salt and sugar reduction, botanicals, natural extracts, enzymes and preservation.

Its distinctive capability is biotechnology. The company has said roughly 40% of its taste solutions are already enabled by fermentation, a platform it has been assembling for more than a decade.

The Q3 Interim Management Statement of 22 October 2026 is the freshest read available on ingredient demand. Volume grew 3.6% over the first nine months and 4.1% in the third quarter, ahead of end market growth, with the gain led by snacks, meat, dairy and beverage end-use markets. Pricing was -0.6% year to date and +0.2% in Q3 as first-half deflation turned to inflation. Group EBITDA margin expanded 50 basis points, primarily driven by the Accelerate 2.0 programme, and full-year constant currency adjusted EPS guidance of 6% to 10% was maintained. Foodservice volumes grew 5.0% and emerging markets 4.9%. Net debt stood at €2.4 billion at the end of September.

For the 2025 full year, reported on 17 February 2026, Kerry recorded revenue of €6.8 billion and EBITDA of €1,208 million against €1,188 million, with EBITDA margin moving from 17.1% to 17.9%.

Technology investment in that year included a Biotechnology Centre in Leipzig, enzyme capacity in Cork, cocoa taste capability in Grasse and coffee extraction in Pennsylvania. The signal: reformulation demand holds up even when headline revenue is flat.

Roquette

Roquette converts wheat, corn, peas, seaweed and cellulose into starches, polyols, fibres and plant proteins, alongside pharmaceutical excipients. It touches the report’s Sweeteners, Thickeners, Stabilizers and Emulsifiers and Binders, and Nutrients segments.

Its distinctive capability is pea protein at industrial scale, now extended across a NUTRALYS range covering pea, wheat and fava bean.

On 23 February 2026 the company launched NUTRALYS Pea 850F from Lille, a pea protein isolate engineered to reduce vegetal off-notes at ingredient level rather than through masking agents. Roquette positioned it for dairy alternatives, ready-to-mix and ready-to-drink beverages and specialised nutrition, including high-protein products developed for GLP-1 users, and noted it is not classified as a major allergen. Further launches followed, including the NEOSORB AG polyol range on 10 June 2026.

The H1 2026 results published on 24 September 2026 give the financial picture. Turnover reached €2,586 million, up 9% on €2,371 million a year earlier, with Current EBITDA of €337 million, up 18% from €285 million. Like-for-like volumes rose 2%. Within Nutrition & Bioindustry, sales were €1,888 million and Current EBITDA €141 million, up 8% like-for-like with margin improvement of 75 basis points; the proteins business grew volumes and sales, with momentum in Europe, North America and Asia including continued progress in India. A €600 million perpetual hybrid bond issue in April 2026 strengthened the balance sheet.

Roquette serves plant-based and high-protein formulators. Its move says the competition in plant protein ingredients has shifted to sensory performance.

Tate & Lyle

Tate & Lyle supplies speciality food and beverage solutions across three platforms sweetening, mouthfeel and fortification including pectin and speciality gums. It maps to the Sweeteners, Thickeners, Stabilizers and Nutrients segments.

Its distinctive capability is combining those three platforms in a single reformulation brief, so a customer cutting sugar can address the texture consequence with the same supplier.

The results for the year ended 31 March 2026 record the build-out. Integration of CP Kelco was completed, delivering US$24 million of synergies in the year against US$6 million the year before and taking annualised run-rate synergies to US$50 million, a year ahead of schedule, alongside US$53 million of productivity savings. The company invested £86 million in innovation and solution selling in areas such as solution chassis and nutrition science. The value of the new business pipeline rose 15% in year, the cross-selling pipeline more than doubled in the second half, and New Product revenue reached approximately £336 million, up 9% like-for-like.

CP Kelco came from J.M. Huber Corporation also named on the report’s roster completing on 15 November 2024 for a final consideration of £1,446 million.

On 8 June 2026 Tate & Lyle agreed a recommended all-cash acquisition by Ingredion at 595 pence a share, about £2.7 billion, with shareholders approving on 28 July 2026. It serves beverage, dairy and bakery formulators working on sugar reduction with texture intact.

What does a successful capability build look like?

The Tate & Lyle and CP Kelco sequence is the clearest worked example in the category.

Starting point. Tate & Lyle’s reformulation offer was strong on sweetening, but customers increasingly arrived with a combined brief: cut the sugar, hold the mouthfeel, add the fortification. The texture half of that brief sat outside the portfolio, so the conversation kept ending at a capability the company did not own.

The turning move. On 15 November 2024 it completed the acquisition of CP Kelco from J.M. Huber Corporation for a final consideration of £1,446 million, bringing pectin, speciality gums and other nature-based ingredients in-house and creating a three-platform portfolio.

The result. By the year ended 31 March 2026 the integration was complete. Synergies of US$24 million in the year lifted the annualised run-rate to US$50 million, a year ahead of plan. More tellingly for a capability thesis, the commercial evidence appeared in the pipeline before it appeared in revenue: the value of the new business pipeline rose 15% in year and the cross-selling pipeline more than doubled in the second half, with New Product revenue around £336 million, up 9% like-for-like. In June 2026 Ingredion agreed to acquire the enlarged business for about £2.7 billion, in a combination expected to complete in the second half of 2027 with combined annual sales approaching US$10 billion.

The transferable lesson: when the gap is a platform rather than a product, buying it is faster than building it and the cross-sell pipeline is the number that tells you whether it worked.

How do these five complement one another?

They occupy genuinely different parts of the same supply map, which is why a large manufacturer typically works with several at once rather than choosing between them.

Givaudan brings flavour creation with regional powder and liquid manufacturing, which suits brands that need local taste development and short lead times. Glanbia brings custom premix and functionally optimised nutrients, which suits active nutrition and nutraceutical brands that buy a documented blend rather than individual actives.

Kerry brings fermentation-derived taste and reduction technologies, which suits retail and foodservice customers renovating nutritional profiles at scale. Roquette brings plant proteins, starches, polyols and fibres from its own crop base, which suits high-protein and plant-based formulators who need the functional ingredient and the protein from one house.

Tate & Lyle brings sweetening, mouthfeel and fortification on one platform, including the hydrocolloids that make a sugar reduction survive contact with texture.

Read together, that is a healthy multi-polar market. The capabilities are complementary rather than substitutable, and the practical consequence for buyers is that a single reformulation brief can usually be met — but rarely by one supplier alone.

What should manufacturers and buyers do now?

For manufacturers, three moves follow from what these five are funding. Match your supplier set to the segment you actually sell into, because a premix house and a flavour house solve different problems and the report’s ten type segments do not move together. Treat regional manufacturing as a procurement criterion, not a nicety Givaudan’s Indonesian and Indiana plants and Glanbia’s Brazilian and Indian facilities exist because customers asked for in-market supply. And where a capability gap is structural rather than technical, partnership or acquisition closes it faster than internal development, as the CP Kelco sequence shows.

For buyers and end-users, the picture is more choice and more capability. Competition has moved from price per kilo to formulation support, which means the useful question in a vendor review is not what an ingredient costs but what the supplier will do when it underperforms on your line. Ask for application support in writing, qualify a second regional source for every single-sourced input, and test reformulation at production line speed rather than pilot scale, since validation that holds at pilot volume does not always hold when throughput doubles.

The food ingredient market rewards reading at company and segment level. A 4.941% global average tells you almost nothing about which supplier can rebuild your product.

Ready to size this for your own portfolio? Cognitive Market Research and Consulting can cut the Food Ingredient Market Analysis to your exact scope, competitor set, type segment, application or region and extend it across adjacent datasets including food additives, plant protein ingredients and pectin. Request the free sample, commission a custom cut of the dataset, set up a live data dashboard tracking supplier developments, or book a consultation with our research team on sourcing, partnership and portfolio decisions for 2027.